NCT03745716 2025-03-18APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)Aprea TherapeuticsPhase 3 Completed154 enrolled 10 charts
NCT06664970 2024-10-30A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With SelinexorPeking Union Medical College HospitalPhase 2 Enrolling by invitation39 enrolled